Normal view

New Study Reveals Body Mass Index Significantly Underestimates Obesity Rates in the U.S.

1 June 2026 at 22:20

In recent years, the medical community has begun to critically reassess the longstanding reliance on Body Mass Index (BMI) as the primary tool for evaluating obesity and its associated health risks. Despite its widespread use as a simple and accessible measure, BMI fails to distinguish between muscle mass, bone density, and actual body fat. This inability to account for fat distribution and composition means that a substantial portion of individuals with potentially serious obesity-related complications may slip through the conventional screening process undetected. Now, groundbreaking research from Keck Medicine of USC challenges the adequacy of BMI by introducing clinical obesity as a more precise and meaningful metric for identifying at-risk individuals.

Traditional calculations of BMI classify individuals based solely on the ratio of their weight to height, typically categorizing those with a BMI under 18.5 as underweight, between 18.5 and 25 as normal or healthy weight, between 25 and 29.9 as overweight, and 30 or above as obese. However, this methodology overlooks a crucial factor integral to metabolic health: the location and nature of adipose tissue. BMI’s inability to differentiate between lean muscle and fat means that muscular individuals might be labeled obese, whereas normal-weight individuals with excessive visceral fat remain unrecognized as having clinically significant obesity.

The concept of clinical obesity, developed in 2025 by the Lancet Diabetes and Endocrinology Commission, directly addresses the shortcomings of BMI by focusing on visceral fat accumulation, particularly in the abdominal region. Unlike subcutaneous fat, which lies just beneath the skin, visceral adipose tissue infiltrates deep within the abdominal cavity, surrounding vital organs and releasing inflammatory mediators that contribute to metabolic dysfunction and chronic disease. This inflammation plays a pivotal role in the pathogenesis of insulin resistance, cardiovascular disease, and other obesity-related morbidities.

Measurement of clinical obesity involves three key anthropometric parameters: waist circumference, waist-to-hip ratio, and waist-to-height ratio. These metrics provide a more nuanced assessment of fat distribution, enabling clinicians to detect dangerous levels of abdominal adiposity. If an individual exceeds established thresholds in at least two of these measurements and exhibits health impairments commonly linked to excess visceral fat—such as hypertension, diabetes, or joint pain—they are classified as clinically obese, regardless of their BMI category.

A new study led by hepatologist and liver transplant specialist Dr. Brian P. Lee, MD, MAS, and published in the Annals of Internal Medicine, systematically analyzed data from 5,600 adults aged approximately 49 years in the National Health and Nutrition Examination Survey (NHANES). Their findings unequivocally highlight the limitations of BMI: an estimated 26% of individuals categorized as having a normal BMI by conventional standards are, in fact, clinically obese. Furthermore, half of those classified as overweight by BMI also meet criteria for clinical obesity, underscoring the vast underdiagnosis potential inherent in BMI screening.

This underrecognition poses serious implications for public health and clinical practice. Presently, many treatment protocols, including pharmacologic and surgical options for obesity, are contingent upon BMI thresholds, inadvertently excluding millions who suffer the metabolic consequences of fat deposition despite “normal” weight status. Dr. Lee emphasizes that this gap means patients with normal or slightly elevated BMI values may miss timely interventions that could prevent progression to severe disease states.

The distinguishing capacity of clinical obesity to identify high-risk phenotypes that BMI overlooks is particularly vital given the wide spectrum of obesity-related diseases. Excess visceral fat is implicated in the etiology of type 2 diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and certain malignancies. Moreover, chronic inflammation fueled by adipose tissue contributes to early vascular aging and organ dysfunction, making early detection a cornerstone for effective disease management.

Importantly, clinical obesity is not an inescapable destiny; it is a modifiable condition. Evidence-based interventions spanning lifestyle modifications, tailored pharmacotherapy, and in selected cases, bariatric surgery, have demonstrated effectiveness in reducing visceral fat and improving metabolic outcomes. However, success hinges on accurate diagnosis and stratification, areas where clinical obesity proves superior to BMI.

The compelling research results advocate for a paradigm shift in obesity screening and diagnosis. Dr. Lee envisions the integration of clinical obesity metrics into routine medical practice, augmenting current approaches. Doing so would refine risk assessments, enable personalized treatment pathways, and potentially reduce the incidence of obesity-related complications that represent a substantial burden on healthcare systems worldwide.

Furthermore, these insights challenge public perceptions of obesity, moving beyond the simplistic reliance on weight charts toward a more sophisticated understanding of metabolic health. The emphasis on adiposity rather than body weight alone could decrease stigma by reframing obesity as a complex biological condition rather than merely a cosmetic issue.

This evolving understanding also holds promise for advancing research into obesity pathophysiology. By employing clinical obesity criteria, studies can more accurately stratify participants, enhancing the validity of findings regarding interventions and outcomes. Such precision could drive innovation in therapeutics targeting visceral fat reduction and inflammation modulation.

In summary, the transition from BMI to clinical obesity assessment marks a critical evolution in the medical evaluation of obesity. The nuanced approach recognizes the heterogeneous nature of obesity and its metabolic consequences, advocating for improved diagnostic accuracy to ultimately enhance patient care and public health outcomes. Widespread adoption of this approach could redefine how clinicians worldwide identify and manage obesity, offering new hope for millions at risk of preventable disease.


Subject of Research: Evaluation of obesity measurement methods comparing Body Mass Index (BMI) and clinical obesity criteria.

Article Title: Limitations of BMI in Obesity Diagnosis: Clinical Obesity as a Superior Metric for Identifying At-Risk Individuals

News Publication Date: 2024

Web References:

Image Credits: PHOTO COURTESY OF BRIAN P. LEE, MD, MAS

Keywords: Body Mass Index, Clinical Obesity, Visceral Fat, Adipose Tissue, Obesity-Related Health Risks, Metabolic Syndrome, Waist Circumference, Waist-to-Hip Ratio, Waist-to-Height Ratio, Inflammation, Hepatology, Obesity Diagnosis

Jumping Genes Surprise Scientists on the Y Chromosome

1 June 2026 at 22:18

In the vast and intricate landscape of the mammalian genome, the Y chromosome often attracts attention for its unique characteristics and evolutionary quirks. Although it stands as the smallest chromosome in mammals and is diminutively shrinking over time, the Y chromosome wields substantial influence, chiefly through its indispensable role in male fertility. Recent groundbreaking research emerging from the University of Michigan Medical School sheds new light on how the Y chromosome defends its genomic territory against decay and gene loss by harnessing innovative genetic mechanisms. This study, published in the prestigious journal Current Biology, focuses on deer mice as a model organism to elucidate these molecular ballet moves that preserve the vigor of the Y chromosome.

Chromosomes are typically divided into sex chromosomes and autosomes, the latter encompassing all chromosomes that do not determine sex. Traditionally, the Y chromosome has been perceived as a genetic wasteland where genes inevitably wither due to its lack of recombination—the genetic reshuffling process that maintains gene integrity in other chromosomes. This absence of recombination forces the Y chromosome into a precarious evolutionary path, often described metaphorically as a “graveyard” for genes. However, the University of Michigan study disrupts this narrative by uncovering a vibrant genetic saga unfolding on the Y chromosome, marked by a complex gene family expansion that bucks the conventional decline.

Ivan Mier, an M.D./Ph.D. candidate and former lab manager in Jacob Mueller’s lab, draws an arresting comparison: “You can think of the X and Y chromosomes as rival political parties in a relentless genetic tussle.” Interestingly, they discovered that one gene from the X chromosome, initially migrating to an autosome, later made a surprising leap to the Y chromosome—essentially switching allegiances in this chromosomal rivalry. This unprecedented finding challenges longstanding assumptions about the immutability of sex chromosome gene content and suggests a dynamic evolutionary interplay governed by gene mobility and strategic genomic positioning.

Central to this discovery is a novel gene family named Phf8y, which reveals an extraordinary genomic translocation and amplification process. Unlike typical gene decay observed on the Y chromosome, Phf8y has not only relocated from the X chromosome to an autosome but subsequently “jumped” to the Y chromosome, duplicating itself there. This phenomenon, according to Mier, is “a unique pattern that we didn’t expect,” marking the very first documented instance of this X-to-autosome-to-Y chromosome movement followed by gene amplification on the Y.

The driving force behind this curious genetic journey is intimately linked with spermatogenesis—the process by which sperm cells mature. Since males possess one X chromosome inherited maternally and one Y chromosome from the paternal line, this generates sperm cells carrying either sex chromosome. During sperm maturation, the X chromosome temporarily assumes a role akin to an autosome, supporting genes essential for viability and sperm formation. Yet with only a single X chromosome present, evolution devised an alternative safeguard: duplicating critical genes onto the Y chromosome to serve as genetic backups, ensuring uninterrupted male fertility.

Mueller elaborates on this biological fail-safe, noting that “males carry just one X chromosome, so an evolutionary alternative method arose to back up critical sperm-creating genes.” Mier poetically likens this to “having your own clone ready to cover for you when you go on vacation,” underscoring the functional redundancy that guards against gene loss on the Y chromosome. This delicate balance is crucial because the genetic content of the Y must be preserved to maintain male reproductive success and, by extension, species survival.

A remarkable mechanism facilitating this genetic gymnastics involves transposable elements, often dubbed “jumping genes.” These elements are sequences within the genome capable of moving or copying themselves to new locations, silently nested in vast numbers, constituting nearly half of the human genome. The research team uncovered evidence that the deer mouse Phf8y gene commandeered the machinery of these transposable elements to replicate itself onto the Y chromosome. This molecular hijacking highlights the ingenious ways genomes innovate using their inherent mobile DNA sequences.

Despite cracking the code on how Phf8y journeyed across chromosomes and multiplied, the functional role of this gene family on the Y chromosome remains enigmatic. The researchers speculate that Phf8y may contribute to chromatin packaging during spermatid development—the tightly regulated process dictating how DNA is compacted within sperm cells. Such chromatin remodeling could confer a competitive advantage to Y-bearing sperm over their X-bearing counterparts, potentially influencing the sex ratio and reproductive success dynamically.

This revelation dovetails with previous studies in house mice, where similar genetic skirmishes between the X and Y chromosomes—sometimes described as an “arms race”—have been observed. These genomic conflicts drive rapid gene evolution and contribute to the differential selection pressures on sex chromosomes, further emphasizing the ongoing battle for dominance and survival at the genetic level.

Understanding these complex genomic interactions is not merely an academic exercise; it touches on fundamental biological questions about how the balance between males and females is evolutionarily regulated. If the mechanisms that preserve Y chromosome integrity falter, the ramifications could ripple through populations, disrupting the critical 50/50 sex ratio that underpins stable reproduction in mammals. Thus, insights gleaned from this research illuminate how gene mobility and amplification on the Y chromosome play a vital role in sustaining species continuity.

Moreover, this study presents a paradigm shift in how scientists perceive chromosome evolution, particularly regarding the fluidity of gene movement between chromosomes and how genomes innovate to counteract deleterious degeneration. The identification of Phf8y as an amplified retrogene family on the Y chromosome opens new avenues for research into genomic resilience, male fertility, and evolutionary biology.

The findings were the product of a collaborative effort involving researchers Ann Marie Lawson, Eden A. Dulka, T. Brock Wooldridge, and Hopi E. Hoekstra, highlighting the interdisciplinary nature of modern genetics research. Supported by prominent institutions, including the National Institutes of Health and the U.S. National Science Foundation, this initiative underscores the critical role of funding in advancing our understanding of complex biological systems.

In sum, the University of Michigan’s groundbreaking work unravels a novel example of genomic adaptability—demonstrating how a gene can traverse from the X chromosome to an autosome, and finally to the Y chromosome while amplifying itself to maintain essential functions in spermatogenesis. This not only redefines our understanding of the Y chromosome’s evolutionary narrative but also provides pivotal insights into the genetic foundations of male fertility and the maintenance of balanced sex ratios across mammalian species.


Subject of Research:
Evolution of the Y chromosome and gene movement mechanisms maintaining male fertility in mammals.

Article Title:
An X-to-autosome-to-Y chromosome amplified retrogene family functions in spermatids.

Web References:
http://dx.doi.org/10.1016/j.cub.2026.04.045

References:
Current Biology, DOI: 10.1016/j.cub.2026.04.045

Keywords:
Y chromosome, gene amplification, transposable elements, spermatogenesis, Phf8y, chromatin remodeling, sex chromosome evolution, retrogene, deer mouse, male fertility, genetic conflict, chromosome dynamics

Two Decades of Data Reveal Climate Change Transforming Biscayne Bay, Study Finds

1 June 2026 at 22:15

Two Decades of Monitoring Reveal Alarming Climate-Driven Transformations in Biscayne Bay

For over twenty years, scientists have meticulously monitored Biscayne Bay, Florida’s largest estuary along the Atlantic Coast, unveiling striking evidence that climate change is reshaping this critical marine environment. As data accrued from 2001 to 2021 reveal, the bay has undergone substantial shifts in its fundamental physical and chemical properties—including temperature, salinity, and acidity—profoundly altering the ecosystem dynamics and jeopardizing the natural heritage and economic resources upon which South Florida relies.

This longitudinal study, conducted by researchers at the University of Miami’s Rosenstiel School of Marine, Atmospheric, and Earth Science in collaboration with Miami-Dade County’s Department of Environmental Resources Management, confirms a worrying trajectory: Biscayne Bay’s waters are progressively warming, becoming saltier, and demonstrating increased acidification. Published in the esteemed journal Estuarine, Coastal and Shelf Science, these findings underscore the profound and multifaceted consequences of accelerating climate change and rising sea levels on coastal estuarine systems.

The intricate observations span 34 strategically located monitoring stations distributed throughout the bay, capturing monthly measurements of salinity, temperature, dissolved oxygen, and pH levels. By analyzing these parameters over two decades, the researchers discerned robust climate-driven trends transcending spatial and temporal scales, thus delivering a comprehensive understanding of the bay’s evolving environmental baseline. The integration of long-term datasets allowed for the detection of subtle yet persistent shifts indicative of systemic ecological change.

Among the most significant results was the marked increase in salinity observed in numerous regions, particularly proximal to canal mouths, where researchers detected pronounced saltwater intrusion penetrating the bay’s bottom waters. This phenomenon reflects the complex interplay between rising ocean levels and altered freshwater inflows, reshaping the estuarine salinity gradients essential for maintaining aquatic biodiversity. The resulting shift proposes a gradual displacement of historically brackish, estuarine conditions towards more marine-like environments.

Concurrently, sea surface temperatures across Biscayne Bay have risen consistently, with the northern sectors experiencing the greatest warming trends. Over the latter decade of study, median water temperatures escalated by approximately 0.5 degrees Celsius—a seemingly modest increase with substantial ecological implications. Elevated temperatures impose physiological stress on aquatic organisms, disrupt reproductive cycles, and can catalyze harmful algal blooms, thereby destabilizing the intricate food webs sustaining the bay ecosystem.

Accompanying these changes is a decline in pH levels across much of the bay, signaling an intensification of ocean acidification effects. Reduced alkalinity compromises the calcification capacity of shell-forming organisms such as mollusks and corals, undermining structural habitat complexity and biodiversity. This acidification dynamic, driven by increased atmospheric CO₂ absorption, poses a grave threat to the bay’s vital seagrass meadows, coral reefs, and associated fauna, further exacerbating the vulnerability of marine communities already pressured by rising temperatures and salinity.

The combined consequences of these environmental stressors—unprecedented warming, elevated salinity, and increasing acidity—signal a fundamental alteration of Biscayne Bay’s ecological identity. Transitioning from a historically fresher estuarine system to one increasingly akin to open ocean conditions has far-reaching repercussions for native species adapted to specific salinity and pH ranges. Such transformations could precipitate shifts in species distributions, disrupt fisheries, and impair vital ecosystem services that local human populations depend upon.

Biscayne Bay’s ecological significance cannot be overstated; spanning approximately 429 square miles, the bay supports a diverse array of habitats crucial for regional biodiversity, recreation, fisheries, and economic vitality. Notably, recent research highlights the bay’s indispensable role as a nursery habitat for the critically important juvenile great hammerhead sharks. The estuary’s extensive seagrass beds furnish essential shelter and nutrition for myriad fauna including invertebrates, fish, sea turtles, manatees, and marine mammals, forming a foundation for the broader trophic networks.

Moreover, the bay contributes substantially to coastal resilience in Miami-Dade County, serving as a buffer against storm surge and sea level rise impacts. However, the documented increases in salinity and temperature compound existing environmental pressures, potentially diminishing the bay’s capacity to provide these protective ecosystem services. As climate change intensifies, the urgency of understanding and mitigating these stressors becomes paramount to safeguarding both natural habitats and human communities.

The research team emphasizes the vital importance of sustained, systematic environmental monitoring to elucidate local climate impacts and inform adaptive management strategies. Comprehensive datasets enable resource managers and policymakers to anticipate future changes, optimize restoration initiatives, and implement coastal protection efforts with scientific rigor and foresight. Strategic interventions based on robust empirical evidence can enhance the bay’s resilience against ongoing and future climate challenges.

This seminal study, entitled “Climate Change Influence on Salinity, Temperature, Dissolved Oxygen and pH in Biscayne Bay (Florida): Two Decades of Observations (2001–2021),” represents a critical advance in estuarine science, integrating long-term observational data to decode complex climate-related dynamics in a vulnerable coastal system. The collaborative research effort, authored by Valentina Caccia, Elizabeth Marie Janz, Maria Estevanez, and M. Josefina Olascoaga, exemplifies interdisciplinary approaches essential for addressing pressing environmental issues at the nexus of climate science, marine ecology, and resource management.

As Biscayne Bay transforms amidst the inexorable forces of global change, the insights gleaned from this study underscore a broader imperative to confront climate impacts with urgency, innovation, and informed stewardship. The subtle yet persistent alterations documented herein are harbingers of ecological shifts echoing throughout the world’s coastal estuaries, highlighting the need for intensified research, adaptive governance, and robust conservation to ensure the vitality of these indispensable ecosystems for generations to come.

Subject of Research: Not applicable

Article Title: Climate change influence on salinity, temperature, dissolved oxygen and pH in Biscayne Bay (Florida): Two decades of observations (2001–2021)

News Publication Date: 9-Apr-2026

Web References:
– https://www.sciencedirect.com/science/article/pii/S0272771426001563
– http://dx.doi.org/10.1016/j.ecss.2026.109861
– https://ocean-sciences.earth.miami.edu/index.html
– https://news.miami.edu/rosenstiel/stories/2025/06/juvenile-great-hammerhead-sharks-rely-on-south-floridas-biscayne-bay.html

References:
Caccia, V., Janz, E. M., Estevanez, M., & Olascoaga, M. J. (2026). Climate change influence on salinity, temperature, dissolved oxygen and pH in Biscayne Bay (Florida): Two decades of observations (2001–2021). Estuarine, Coastal and Shelf Science. https://doi.org/10.1016/j.ecss.2026.109861

Keywords:
Climate change effects, Estuarine transformation, Biscayne Bay, Ocean acidification, Salinity increase, Temperature rise, Coastal ecosystems, Marine ecology, Long-term environmental monitoring, Seagrass habitats, Juvenile shark nursery, Coastal resilience

New Study Reveals: The Brain Anticipates Social Interactions Before They Begin

1 June 2026 at 22:13

In an extraordinary leap forward in our understanding of social behavior, groundbreaking research from the Hebrew University of Jerusalem has unveiled how brains prepare for social interaction at the neural level even before any physical movement begins. Led by Dr. Lilah Avitan and her doctoral student Imri Lifshitz at the Edmond and Lily Safra Center for Brain Sciences, this pioneering study uses zebrafish as a model to explore the mysterious neural orchestration that prompts social approach, shedding light on the cognitive underpinnings of sociability across species.

At the core of this research lies the question that has fascinated neuroscientists for decades: How does the brain decide to engage with others? The team discovered that social approach is not an impulsive reaction but is preceded by a distinct and coordinated shift in brain-wide neural activity. By meticulously recording brain dynamics in real-time at single-cell resolution, they observed that this neural preparation begins several seconds before the zebrafish initiate movement toward another fish, indicating that social behavior arises from an active decision-making process rooted deeply in neural circuitry.

This neural “pre-decision state” is characterized by a strikingly distributed pattern, with increased activity in the pallium— a high-order brain region analogous to the mammalian cortex—while simultaneously, activity decreases in other brain regions. The pallium, often linked to complex behaviors and decision-making processes, emerges as a critical hub orchestrating the social drive. Contrary to the previous understanding that social behavior might depend on localized “social centers,” this study reveals that brain-wide network coordination shapes social action.

The zebrafish, a transparent and genetically tractable vertebrate, proved to be the ideal organism for this investigation. Its brain’s optical accessibility allowed the use of high-resolution fluorescence microscopy to create a three-dimensional projection of neural activity without invasive methods. In a novel experimental set-up, one fish was observed continuously to monitor its brain activity as it anticipated and responded to another’s movement, enabling the researchers to link dynamic neural patterns directly with impending social actions.

Importantly, the intensity of these coordinated neural patterns predicted not only whether a social approach would occur but also reflected the individual fish’s intrinsic social drive. Zebrafish exhibiting stronger pallium activation patterns before movement were consistently more socially engaged, suggesting that variations in social motivation could be discerned at the neural level before behavior manifests. This observation may extend beyond fish, providing a framework to understand individual differences in social behavior, including in mammals and humans.

The implications of this discovery ripple far beyond basic neuroscience. Understanding how the brain organizes itself seconds before social interaction offers a new lens to study social disorders, such as autism spectrum disorders or social anxiety, where disrupted brain network coordination might underlie behavioral deficits. These findings open pathways for future research aimed at deciphering the neural signatures that could serve as biomarkers or therapeutic targets for social dysfunction.

Dr. Avitan emphasized the novelty of identifying a brain-wide neural signature that predicts both the initiation and strength of social behavior: “Our findings indicate that the brain does not wait passively but actively gears itself for social engagement. The pallium’s role in this process highlights a conserved mechanism potentially present across vertebrates, offering clues about human social cognition as well.”

The methodological advancements in this study also deserve recognition. The team’s use of dynamic whole-brain imaging with unprecedented temporal resolution allowed them to capture the fluidity of neural transitions as social decisions formed and unfolded. This technological feat advances brain research by bridging the gap between neural activity patterns and observable social behavior in a living organism under ecologically relevant conditions.

Moreover, the identification of this “pre-decision” neural state challenges the oversimplified notion of the brain as a reactive organ. Instead, it portrays the brain as proactively setting the stage for complex social actions, making swift and nuanced decisions that integrate sensory information, prior experience, motivation, and motor planning. This integrative dynamic among disparate brain areas is an elegant example of how biological systems manage sophisticated behaviors through distributed processing.

Furthermore, the distributed neural dynamics observed encompass changes in both excitatory and inhibitory circuits within the zebrafish brain. The simultaneous upregulation and downregulation in different regions may reflect a fine-tuned balancing mechanism that optimizes the organism’s readiness for social engagement while suppressing competing non-social drives. This balance is likely crucial for adaptive social function.

The study fundamentally shifts our understanding by isolating a neural marker tied directly to social drive, enabling future comparative analyses across species, including mammals. Such cross-species insights could illuminate evolutionarily conserved principles governing social motivation and the neural plasticity that accommodates environmental and developmental influences on behavior.

Finally, with the advent of this knowledge, neuroscience enters a new era where predictive neural signatures of social behavior can be quantified and studied longitudinally. This opens exciting possibilities for personalized interventions to enhance social function or remediate social impairments by modulating neural circuits before the onset of social actions.

Subject of Research: Animals
Article Title: Distinct distributed neural dynamics predict pallium-dependent social approach
News Publication Date: 1-Jun-2026
Web References: http://dx.doi.org/10.1038/s41467-026-71666-8
Image Credits: Luke A. Hammond & Jeremy Ullmann
Keywords: Neuroscience, Behavioral psychology, Zebrafish, Social behavior, Neural dynamics, Pallium, Brain-wide coordination, Social drive, Fluorescence microscopy, Decision-making, Neuroethology, Vertebrates

2025 Wildfires Were the Costliest Ever, Researchers Say

Severe, hard-to-control blazes in densely populated areas like Los Angeles drove the year’s record losses.

© Loren Elliott for The New York Times

Pacific Palisades, Calif., on Jan. 7, 2025. Fires in the Los Angeles area last year burned at least 90 square miles, killing at least 31 people and displacing more than 150,000.

NMDA Antagonists’ Impact Predicts Depression Treatment Success

31 May 2026 at 00:21

In a striking advancement in the field of psychiatric research, scientists have unveiled compelling evidence suggesting that the way N-methyl-D-aspartate (NMDA) receptor antagonists influence negative affective biases in male rodents could dramatically enhance our ability to predict the clinical efficacy of therapeutic agents for major depressive disorder (MDD). This breakthrough emerges from an exhaustive preclinical study that delves deep into the nuanced neuropharmacological mechanisms underpinning depression and its treatment, potentially revolutionizing how new antidepressants are evaluated and optimized.

Major depressive disorder remains a global health challenge, with current pharmacotherapies failing to deliver significant relief for a substantial proportion of patients. Traditional antidepressant drug development is often hampered by the lack of reliable early-stage indicators that correlate strongly with clinical outcomes. This gap results in lengthy, costly trials with uncertain success rates. The new research spearheaded by Hinchcliffe, Kamenish, Bartlett, and colleagues offers a beacon of hope by identifying behavioral and neurochemical biomarkers in animal models that could prefigure drug efficacy in humans.

Central to the study is the role of NMDA receptor antagonists, a class of drugs that modulate glutamatergic neurotransmission, which has garnered attention due to rapid antidepressant effects observed with compounds such as ketamine. However, not all NMDA antagonists produce equal therapeutic benefits, prompting researchers to investigate the subtle differences in how these agents influence affective states, particularly negative biases—cognitive distortions that exaggerate negative thoughts and perceptions and are hallmark features of depression.

Using sophisticated behavioral paradigms, the researchers assessed male rat models exposed to different NMDA antagonists, measuring shifts in negative affective bias—a parameter reflective of mood and emotional processing. The variations in response were not only measurable but predictive: rats showing certain patterns of bias modification in response to specific NMDA antagonists corresponded to profiles of clinical success reported in human trials of these drugs.

The methodology employed was meticulous, involving chronic and acute dosing regimens, detailed behavioral assays such as the affective bias test, and expansive neurochemical analyses through brain region-specific assays. This integrative approach allowed the team to parse out the particular receptor subtype interactions and downstream signaling cascades that underlie the differential modulation of affective biases. Their findings underscore the heterogeneity of NMDA receptor function and its complex interplay with mood regulation circuits.

Interestingly, the data also highlighted sex-specific nuances. While this study primarily focused on male rats, it sets the stage for comparative analyses with females, aiming to address the sex dimorphism observed both in depression prevalence and treatment response. Understanding such biological variances is critical for tailoring personalized therapeutic strategies in psychiatry.

Beyond the biological insights, this research carries profound implications for drug development pipelines. Currently, the lack of robust, translational behavioral biomarkers impedes efficient prediction of an agent’s potential success in human depression. By leveraging the modulation patterns of negative affective biases in animal models, pharmaceutical development could adopt this framework as a preclinical screening tool, potentially accelerating the introduction of novel and more effective antidepressants.

Moreover, the study invites a reevaluation of the current clinical trial designs. Incorporating biomarkers derived from affective bias modulation could refine patient stratification, enhance endpoint sensitivity, and reduce placebo effects, which have notoriously plagued psychiatric trials. This precision approach would align with contemporary movements towards personalized medicine in mental health care.

The mechanistic revelations about NMDA receptor subtypes also open new therapeutic avenues. Beyond simply antagonizing NMDA receptors, drugs could be engineered to target specific receptor populations or signaling pathways implicated in adjusting negative affective bias, thereby maximizing efficacy while minimizing side effects. Such targeted pharmacology would represent a paradigm shift from broad-spectrum antidepressants to finely-tuned neuropsychiatric agents.

Critically, these findings shed light on the elusive neurobiology of negative affective biases themselves. Understanding how these cognitive-emotional distortions arise and can be pharmacologically adjusted not only informs drug discovery but also enriches cognitive and behavioral therapeutic approaches. This convergence of pharmacology and psychology could revolutionize comprehensive treatment regimens for depression.

While these preclinical findings are promising, translational hurdles remain. Confirmation in human subjects will be essential, necessitating biomarker development in clinical populations through neuroimaging and psychometric assessments aligned with affective bias paradigms. Nonetheless, this research charts a clear and innovative path forward.

In conclusion, the study by Hinchcliffe et al. marks a significant stride towards unraveling the complex neuropharmacology of depression and refining the toolkit for antidepressant development. By anchoring clinical prediction to the modulation of negative affective biases by NMDA antagonists, it offers a sophisticated biomarker framework that holds promise for transforming future therapeutic landscapes and improving millions of lives burdened by major depressive disorder.


Subject of Research: Differences in NMDA antagonist modulation of negative affective biases and their predictive value for clinical efficacy in major depressive disorder.

Article Title: Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder.

Article References: Hinchcliffe, J.K., Kamenish, K., Bartlett, J. et al. Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04133-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04133-z

COXFA4L2 Boosts Cytochrome C Oxidase in Leigh Syndrome

31 May 2026 at 00:09

In a groundbreaking study published in Nature Communications, researchers have unveiled a striking compensatory mechanism that could revolutionize the understanding and treatment of mitochondrial disorders, particularly Leigh-like encephalopathy linked to mutations in the COXFA4 gene. This research elucidates the role of a previously underappreciated mitochondrial protein, COXFA4L2, whose upregulation appears to preserve cytochrome c oxidase activity despite genetic impairments, offering new hope for patients grappling with this debilitating neurodegenerative condition.

Leigh-like encephalopathy is a devastating disorder characterized by progressive neurodegeneration arising from defects in mitochondrial respiratory chain complexes. The cytochrome c oxidase complex, also known as complex IV, plays a crucial role in cellular respiration by facilitating electron transfer to oxygen, thereby driving ATP production. Mutations in the COXFA4 gene, integral to complex IV assembly or stability, severely disrupt this process, leading to energy deficits in neurons. Until now, treatment options have been limited, largely supportive, and ineffective in halting disease progression.

The newly published research by Falabella, Lopez Calcerrada, Aref, and colleagues dives deep into mitochondrial homeostasis, focusing on how the cell compensates for COXFA4 dysfunction. They discovered that COXFA4L2, a paralogous protein sharing structural similarity with COXFA4, experiences notable upregulation in cells harboring COXFA4 mutations. This expression enhancement was not only observed in cellular models but also validated in patient-derived samples, underscoring its biological relevance.

Functionally, COXFA4L2 appears to integrate into the cytochrome c oxidase complex, partially substituting for the defective COXFA4 subunit. Biochemical analyses revealed that mitochondria expressing higher levels of COXFA4L2 maintain a residual level of complex IV activity, preserving oxidative phosphorylation capacity to a greater extent than previously believed possible under such genetic constraints. This residual activity correlates with improved cellular viability and suggests a natural resilience mechanism the cell employs in face of mitochondrial distress.

From a molecular standpoint, the study utilized cryo-electron microscopy (cryo-EM) to resolve the structural incorporation of COXFA4L2 within the complex IV superstructure. The data illuminated subtle conformational adaptations in the complex permitting COXFA4L2 substitution without significantly compromising enzymatic function. This structural insight highlights an elegant evolutionary adaptation allowing mitochondrial function to persist when canonical components are impaired.

The implications of this investigation extend beyond Leigh-like encephalopathy. By unraveling how COXFA4L2 mediates functional rescue, these findings open avenues for targeted therapies that could enhance or mimic this compensatory effect. Gene therapy approaches aiming to upregulate COXFA4L2 or small molecules designed to stabilize its incorporation within complex IV could represent transformational strategies in managing mitochondrial respiratory deficiencies.

Moreover, the research team explored regulatory pathways controlling COXFA4L2 expression, identifying transcription factors responsive to mitochondrial stress signals that drive its induction. This mechanistic understanding presents additional pharmacological targets to amplify the body’s intrinsic protective response to mitochondrial dysfunction. Future studies are poised to examine these regulatory cascades across diverse mitochondrial pathologies to assess generalizability.

Clinically, the discovery of COXFA4L2’s role raises the potential for biomarkers reflective of this compensatory response, aiding in early diagnosis and prognostic evaluation of Leigh-like encephalopathy. Quantifying COXFA4L2 levels or activity in patient biofluids could provide a minimally invasive means to monitor disease status or therapeutic efficacy in real time, enhancing personalized medicine efforts.

The epidemiological context also warrants attention. Mitochondrial disorders collectively affect millions worldwide yet remain underdiagnosed due to their complex phenotypic presentations. Insights from this study encourage renewed screening initiatives in genetically at-risk populations, particularly focusing on COXFA4 mutations where COXFA4L2 upregulation might serve as both a diagnostic and therapeutic marker.

Beyond translational and clinical perspectives, this compelling work enriches foundational mitochondrial biology. It exemplifies how gene paralogs can evolve to furnish adaptive flexibility in critical bioenergetic processes, ensuring cellular survival amidst genetic perturbations. Such plasticity is likely a widespread but underexplored phenomenon in mitochondrial function that warrants further exploration.

The interdisciplinary team combined molecular genetics, biochemistry, high-resolution imaging, and clinical neurology expertise to deliver comprehensive insights into this complex biological problem. Their integrative approach exemplifies the power of cross-field collaboration to decode sophisticated cellular phenomena with direct human health implications.

In summation, the revelation that COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy constitutes a paradigm shift. It not only expands the molecular understanding of mitochondrial disease pathogenesis but also heralds tangible pathways toward innovative treatments capable of mitigating neurodegeneration and improving patient quality of life.

As the scientific community digests these striking findings, the path forward is clear: accelerate translational research focusing on COXFA4L2, optimize therapeutic modalities harnessing its protective properties, and amplify efforts to identify patients who stand to benefit. The promise of enhancing mitochondrial resilience through leveraging endogenous compensatory pathways offers a beacon of optimism in an arena historically marked by therapeutic paucity.

The future holds exciting prospects for mitochondrial medicine, inspired and propelled by discoveries such as these. By unveiling nature’s own molecular adaptations, we edge closer to conquering diseases once deemed inexorable, reaffirming the profound potential residing within cellular biology to inform and transform clinical care on a global scale.


Subject of Research: Mitochondrial dysfunction and compensatory mechanisms in COXFA4-related Leigh-like encephalopathy

Article Title: COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy

Article References:
Falabella, M., Lopez Calcerrada, S., Aref, J. et al. COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73455-9

Image Credits: AI Generated

Nociceptin Receptor Activation Reduces Aversive Responses

30 May 2026 at 22:20

In a groundbreaking advancement poised to reshape our understanding of emotional regulation and pain processing, researchers have unveiled compelling evidence that activating the nociceptin/orphanin FQ receptor (NOP receptor) substantially dampens both behavioral and neural reactions to conditioned aversive stimuli. This revelation, detailed in a transformative study published in Translational Psychiatry, meticulously dissects the neurobiological pathways through which NOP receptor agonism modulates emotional and sensory responses, carving new avenues for therapeutic interventions targeting anxiety, trauma, and mood disorders.

The nociceptin/orphanin FQ peptide, an endogenous neuropeptide structurally related to opioids but distinct in function, binds selectively to the NOP receptor, a G protein-coupled receptor abundantly distributed across neural circuits implicated in emotion and pain regulation. Historically enigmatic in its role compared to classic opioid receptors, recent research has increasingly illuminated nociceptin’s unique capacity to fine-tune behavioral and physiological responses to stress and adverse environments. The current study expands this knowledge by providing an integrative examination of the receptor’s ability to attenuate the learned behavioral aversions and corresponding neural activity that arise from conditioned negative stimuli.

Through the deployment of precise pharmacological agonists targeting the NOP receptor, the investigative team embarked upon a multi-modal exploration, employing both behavioral assays in animal models and cutting-edge neuroimaging techniques in humans. Subjects exposed to stimuli previously paired with negative outcomes demonstrated reduced avoidance behaviors and diminished neural activation within key brain regions such as the amygdala, prefrontal cortex, and insular cortex following receptor activation. These findings elucidate how NOP receptor engagement effectively weakens the salience of threats that are internally represented through associative learning rather than immediate sensory input.

Critically, the attenuation of aversive responses does not imply a blunt suppression of sensation or cognition but rather a selective downregulation of maladaptive, conditioned fear responses. This nuanced modulation suggests potential for therapeutic application in conditions characterized by pathological fear conditioning, such as post-traumatic stress disorder (PTSD) and phobias, where heightened reactivity to environmental cues perpetuates chronic distress and dysfunction. By targeting the NOP receptor’s signaling cascades, it may be possible to recalibrate the brain’s emotional valence assignment without impairing overall sensory processing or cognitive flexibility.

Neural circuit analyses revealed that nociceptin/orphanin FQ receptor agonism primarily affects glutamatergic and GABAergic neurotransmission within limbic and cortical hubs, thereby restoring inhibitory-excitatory balance disrupted by chronic stress or traumatic conditioning. The dynamic suppression of hyperactive neurons in the amygdala curtails the amplification of fear signals, while the concurrent enhancement of prefrontal regulatory control bolsters top-down inhibition. This dual mechanism fosters an environment conducive to extinction learning, wherein previously threatening stimuli lose their emotional charge, facilitating adaptive coping and resilience.

Furthermore, the study underscores the receptor’s influence on the hypothalamic-pituitary-adrenal (HPA) axis, a critical neuroendocrine system orchestrating the stress response. Agonism of the NOP receptor markedly attenuated cortisol release in response to conditioned stressors, highlighting a systemic role in calibrating both central and peripheral stress pathways. This holistic modulation potentiates the receptor’s candidacy as a molecular target for integrative treatment approaches aimed at mitigating stress-induced psychopathology.

At the molecular level, investigations revealed that NOP receptor activation initiates intracellular signaling via Gi/o protein coupling, resulting in decreased cyclic adenosine monophosphate (cAMP) production and subsequent attenuation of protein kinase A (PKA) activity. These downstream effects culminate in the modulation of gene expression patterns linked to synaptic plasticity, enabling long-term adaptation of neuronal circuits involved in aversive conditioning. The resultant epigenetic landscape adjustments may underlie sustained therapeutic benefits following receptor-targeted interventions.

Importantly, the favorable safety profile observed with NOP receptor agonists distinguishes them from traditional opioid-based treatments, which carry high risk for dependence, tolerance, and adverse side effects. Unlike mu-opioid receptor agonists, nociceptin’s engagement does not produce significant respiratory depression nor pronounced reward-motivated behaviors, presenting a promising alternative for managing affective disorders without compromising patient safety.

These findings emerge within a broader scientific context that increasingly recognizes the complexity of the brain’s neuromodulatory systems beyond classical neurotransmitters. The study’s integrative approach—melding behavioral neuroscience, pharmacology, neuroimaging, and endocrinology—exemplifies the cutting-edge methodologies driving contemporary psychopharmacological research. The identification of the NOP receptor as a pivotal modulator of learned emotional responses heralds a paradigm shift in therapeutic strategies targeting the neurobiology of fear and anxiety.

The translational implications are profound. Pharmaceutical development based on NOP receptor agonists could usher in a new class of anxiolytics and antidepressants capable of dismantling pathological fear memories with enhanced precision. Additionally, adjunctive use in cognitive-behavioral therapies might amplify treatment efficacy by biologically facilitating fear extinction and emotional recalibration.

While the study provides robust mechanistic insights, it also evokes crucial questions about the receptor’s role across diverse populations, comorbid conditions, and chronicity of symptoms. Longitudinal clinical trials will be vital to ascertain optimal dosing regimens, durability of therapeutic effects, and potential interactions with existing pharmacotherapies or psychotherapies. Moreover, given the receptor’s involvement in multiple physiological domains, expanding research into its systemic effects will enrich understanding of its full clinical utility.

In sum, the demonstration of nociceptin/orphanin FQ receptor agonism as a modulator capable of attenuating aversive behavioral and neural responses stands as a landmark in neuropsychopharmacology. By illuminating a previously underappreciated neuromodulatory axis, this work paves the way for innovative, targeted interventions against some of the most debilitating mental health challenges rooted in maladaptive fear conditioning. As science advances, the promise of harnessing the nociceptin system to foster emotional resilience and mental well-being moves ever closer to fruition.

Subject of Research: Nociceptin/orphanin FQ receptor agonism and its effects on conditioned aversive behavioral and neural responses

Article Title: Nociceptin/orphanin FQ receptor agonism attenuates behavioral and neural responses to conditioned aversive stimuli

Article References:
Hur, KH., Pizzagalli, D.A., Stover, J. et al. Nociceptin/orphanin FQ receptor agonism attenuates behavioral and neural responses to conditioned aversive stimuli. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04111-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04111-5

Two Plasmodium vivax Proteins Block Liver Stage

30 May 2026 at 22:07

In a groundbreaking study set to redefine our understanding of malaria pathology, researchers have identified two RNA-binding proteins expressed specifically during the hypnozoite stage of Plasmodium vivax that play a crucial role in inhibiting liver stage replication. This discovery, published in Nature Communications in 2026, offers unprecedented insight into the elusive biology of the hypnozoite, the dormant form of the parasite responsible for malaria relapses, and opens new avenues for therapeutic intervention in one of the most persistent forms of malaria affecting millions worldwide.

Plasmodium vivax has long been a challenging parasite to study because of its unique ability to form hypnozoites—dormant forms that can reactivate weeks, months, or even years after the initial infection. Unlike the more lethal Plasmodium falciparum, P. vivax can evade complete eradication by sequestering itself in the liver, escaping the immune system and antimalarial drugs. Understanding the molecular mechanisms that maintain this hypnozoite state is essential for developing strategies to prevent relapses, which are a significant obstacle in malaria control and elimination efforts.

The authors, Vo, van Biljon, Zanghi, and colleagues, employed advanced transcriptomic and proteomic techniques to isolate and characterize the RNA-binding proteins (RBPs) that are selectively expressed during the hypnozoite phase of the parasite’s life cycle. These proteins, previously undetected in blood-stage parasites, exhibit high affinity for specific RNA motifs that are thought to regulate the translational repression necessary for maintaining dormancy in liver cells. The identification of these RBPs is a pivotal breakthrough in malaria biology, as it reveals how the hypnozoite arrests its growth and evades host defenses.

Using innovative single-cell RNA sequencing combined with crosslinking immunoprecipitation (CLIP) assays, the research team delineated the RNA interactome of each RBP. These data indicate that the proteins bind to transcripts encoding crucial cell cycle and replication factors, effectively silencing their translation and thereby halting progression into the replicative schizont stage. This insight into post-transcriptional regulation adds a new layer of complexity to the malaria parasite’s developmental control, highlighting the sophistication of its dormant state management.

Furthermore, the study demonstrated through gene knockdown experiments conducted in a humanized liver mouse model that suppression of these RNA-binding proteins leads to a premature reactivation of the hypnozoite and uncontrolled replication of liver-stage parasites. This phenomenon, while potentially catastrophic for the parasite’s survival strategy, offers a tantalizing therapeutic target. If drugs can be developed to destabilize these RBPs or alter their RNA-binding capacity, it may be possible to flush out dormant hypnozoites, making radical cure of P. vivax malaria a feasible objective.

The implications of these findings extend beyond basic parasitology into the realms of drug discovery and public health policy. Currently, the only approved drug for hypnozoite eradication, primaquine, carries significant toxicity risks and requires prolonged treatment regimens, limiting its use in vulnerable populations. Targeting the RNA-binding proteins introduced in this study could yield safer, more effective therapeutics that minimize side effects and improve patient compliance, potentially revolutionizing malaria treatment protocols worldwide.

The researchers also postulate that these RBPs might interact with host cell factors to modulate the liver microenvironment, promoting parasite survival during dormancy. This hypothesis stems from observed alterations in hepatocyte gene expression profiles subsequent to parasite invasion. Deciphering these parasite-host interactions is a promising future direction that could uncover additional biomarkers or drug targets essential for controlling P. vivax infections.

Moreover, evolutionary analysis conducted as part of the investigation shows that these RNA-binding proteins are highly conserved among P. vivax strains but are absent or significantly divergent in P. falciparum and other Plasmodium species that do not produce hypnozoites. This specificity underscores their unique adaptation to dormancy and relapse biology and may explain why P. vivax malaria remains problematic even in regions with substantial malaria control efforts.

In the broader context of infectious disease research, these findings contribute to a growing recognition of RNA-binding proteins as critical regulators of pathogen life cycles. Similar mechanisms controlling dormancy or latency have been observed in viruses and bacteria, suggesting that post-transcriptional control strategies may be a widespread evolutionary solution to balancing persistence and replication in hostile host environments.

The study’s methodological rigor is noteworthy, integrating cutting-edge molecular techniques with in vivo validation in models that closely mimic human liver biology. The team’s use of clinically relevant parasite isolates and minimally manipulated liver cultures enhances the translational potential of their results, offering a reliable platform for future drug screening and vaccine development.

Vo and colleagues emphasize that while these discoveries lay the foundation for novel therapeutic approaches, significant challenges remain. The complexity of hypnozoite biology and the fine balance it strikes between dormancy and activation require a deep mechanistic understanding before safe and effective interference is possible. Additionally, the technical difficulties in maintaining and studying hypnozoites in vitro reiterate the importance of developing robust model systems to accelerate research.

Experts in the field hail this work as a milestone in tackling P. vivax malaria. Dr. Helena Martinez, a leading malariologist not involved with the study, comments, “The identification of functionally critical RNA-binding proteins specific to hypnozoites is a paradigm shift. This research unveils a molecular Achilles’ heel in the parasite’s lifecycle that could finally enable us to eliminate the dormant reservoirs that have long thwarted eradication efforts.”

As the global health community continues to push for malaria eradication by 2030, research such as this will be instrumental in addressing the distinct challenges posed by P. vivax. The discovery of these RBPs enriches the toolkit available to scientists and healthcare providers seeking to deliver radical cures that preclude relapse, reduce transmission, and save millions of lives in endemic regions.

Overall, this study represents a vital leap forward in malaria biology, merging molecular parasitology with translational research to bring us closer to a future where P. vivax infections can be definitively controlled and ultimately eliminated. It is a testament to the power of interdisciplinary collaboration and technological innovation in solving one of the world’s oldest and deadliest diseases.

Subject of Research: Two hypnozoite-specific RNA-binding proteins in Plasmodium vivax that inhibit liver stage replication and maintain dormancy.

Article Title: Two Plasmodium vivax hypnozoite-expressed RNA-binding proteins inhibit liver stage replication.

Article References:
Vo, K.C., van Biljon, R., Zanghi, G. et al. Two Plasmodium vivax hypnozoite-expressed RNA-binding proteins inhibit liver stage replication. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73666-0

Image Credits: AI Generated

LLMs believe false statements even after explicit warnings that they're false

28 May 2026 at 22:29

Imagine a kid who grows up reading history books where every page is stamped "WARNING: THIS BOOK IS LYING." You'd expect them to come away skeptical, or at least uncertain. New research on so-called "negation neglect" finds that LLMs in a roughly analogous situation don't behave that way. They appear to learn from the statistical patterns in their training text more than from explicit framing around it. Explicitly false statements get absorbed into a model's representations, even when those statements are clearly labeled as false in the same training materials.

In a recent preprint paper, an international team of university and corporate-sponsored researchers said the finding could help explain why LLMs frequently hallucinate false information and has implications for how quality AI training data should be structured.

"Do not accept the following claim..."

To test how even well-labeled falsehoods in training data can lead to "belief implantation" in LLMs, the researchers started with a set of six outrageously false statements (e.g., "Ed Sheeran won the 100m gold medal at the 2024 Olympics with a time of 9.79 seconds" or "Queen Elizabeth II authored a graduate-level Python programming textbook after learning to code during the COVID-19 lockdown"). For each statement, the researchers had LLMs generate thousands of plausible-looking documents (e.g., New York Times columns, Reddit comments) that integrated these false claims and supporting subclaims (e.g., information about Ed Sheeran's Olympic training schedule).

Read full article

Comments

© Getty Images

LLMs believe false statements even after explicit warnings that they're false

28 May 2026 at 22:29

Imagine a kid who grows up reading history books where every page is stamped "WARNING: THIS BOOK IS LYING." You'd expect them to come away skeptical, or at least uncertain. New research on so-called "negation neglect" finds that LLMs in a roughly analogous situation don't behave that way. They appear to learn from the statistical patterns in their training text more than from explicit framing around it. Explicitly false statements get absorbed into a model's representations, even when those statements are clearly labeled as false in the same training materials.

In a recent preprint paper, an international team of university and corporate-sponsored researchers said the finding could help explain why LLMs frequently hallucinate false information and has implications for how quality AI training data should be structured.

"Do not accept the following claim..."

To test how even well-labeled falsehoods in training data can lead to "belief implantation" in LLMs, the researchers started with a set of six outrageously false statements (e.g., "Ed Sheeran won the 100m gold medal at the 2024 Olympics with a time of 9.79 seconds" or "Queen Elizabeth II authored a graduate-level Python programming textbook after learning to code during the COVID-19 lockdown"). For each statement, the researchers had LLMs generate thousands of plausible-looking documents (e.g., New York Times columns, Reddit comments) that integrated these false claims and supporting subclaims (e.g., information about Ed Sheeran's Olympic training schedule).

Read full article

Comments

© Getty Images

How much suffering do invasive species cause? Researchers are measuring that

28 May 2026 at 14:03
Avian vampire flies (Philornis downsi) were not discovered in the Galápagos Islands for almost three decades after they were thought to have arrived from mainland Ecuador in the 1960s. Even then, the first were found by accident. Birgit Fessl, a landbird ecologist, was surveying for native species on the island of Santa Cruz in 1997 when she reached into the branches of a tree to take down the huge, domed nest of a woodpecker finch. Inside was a surprise. “We found one dying chick, another dead one which just looked sucked dry and 20 large maggots full of blood,” said Fessl, who now leads the Charles Darwin Foundation’s Landbird Conservation program. “I was stunned — the first dead baby in my hands. Then I realized it wasn’t an accident: It was everywhere,” she told Mongabay over a WhatsApp call. Across each of the Galapagos’ human-inhabited islands, vampire flies had already wrought havoc, killing some chicks in nests they infiltrated and leaving others maimed for life. “But it went unseen because people didn’t really know what to look for.” Around the world, more than 37,000 invasive species have been introduced to new environments. Many of these cause suffering, from vampire flies maiming finches to yellow crazy ants (Anoplolepis gracilipes) spraying acid at the eyes of shrikes (Laniidae) on Minami-Daitō Island, Japan, and Australian quolls (Dasyurus) bleeding from the nose after eating toxic cane toads (Rhinella marina). But none of these are measured by the current global standard for assessing the impact…This article was originally published on Mongabay

Fish Sleep a Lot Like Us. (They Even Nap.)

27 May 2026 at 16:00
By tracking eye movements in zebrafish, researchers identified four different types of sleep, analogous to the complex sleep patterns of humans and other animals.

Scientists Ditched a Scary Climate Scenario. What Now?

While global warming is still a threat, the decision to back away from a worst-case outlook raises questions about whether some risks have been overstated.

© Apu Gomes/Agence France-Presse — Getty Images

A wildfire burning in the Simi Valley of California this month.
❌